News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Newron Pharmaceuticals Starts Preclinicals on Compound with Psychiatric Treatment Potential
December 3, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Thomson Financial) - Newron Pharmaceuticals Spa said it has started preclinical development of a compound called NW-3509, which could potentially be used to treat psychiatric and neurological diseases, such as acute mania.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
Cardiovascular disease
Amgen Builds Case for Repatha To Prevent Heart Disease With Late-Stage Data
October 3, 2025
·
1 min read
·
Tristan Manalac
IN PARTNERSHIP WITH PII
Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems
October 2, 2025
·
1 min read
·
BioSpace Insights
Podcast
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
October 1, 2025
·
2 min read
·
Heather McKenzie
Opinion
The Urgent Need To Redefine the Future of UK Biotech
October 1, 2025
·
6 min read
·
Kerstin Papenfuss
